ATE358668T1 - Drogen zur behandlung maligner tumoren - Google Patents

Drogen zur behandlung maligner tumoren

Info

Publication number
ATE358668T1
ATE358668T1 AT00973329T AT00973329T ATE358668T1 AT E358668 T1 ATE358668 T1 AT E358668T1 AT 00973329 T AT00973329 T AT 00973329T AT 00973329 T AT00973329 T AT 00973329T AT E358668 T1 ATE358668 T1 AT E358668T1
Authority
AT
Austria
Prior art keywords
malignant tumors
drugs used
treat malignant
compounds
formula
Prior art date
Application number
AT00973329T
Other languages
English (en)
Inventor
Gunnar Hedlund
Karl Jansson
Stig Joensson
Anders Bjoerk
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Application granted granted Critical
Publication of ATE358668T1 publication Critical patent/ATE358668T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00973329T 1999-10-25 2000-10-24 Drogen zur behandlung maligner tumoren ATE358668T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16140799P 1999-10-25 1999-10-25
SE9903838A SE9903838D0 (sv) 1999-10-25 1999-10-25 Novel compounds
US21281600P 2000-06-21 2000-06-21
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors

Publications (1)

Publication Number Publication Date
ATE358668T1 true ATE358668T1 (de) 2007-04-15

Family

ID=27484521

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00973329T ATE358668T1 (de) 1999-10-25 2000-10-24 Drogen zur behandlung maligner tumoren

Country Status (21)

Country Link
EP (1) EP1224172B1 (de)
JP (1) JP3950337B2 (de)
KR (2) KR100674160B1 (de)
AT (1) ATE358668T1 (de)
AU (1) AU775057B2 (de)
CA (1) CA2386775C (de)
CZ (1) CZ298534B6 (de)
DE (1) DE60034240T2 (de)
DK (1) DK1224172T3 (de)
EE (1) EE200200207A (de)
ES (1) ES2280258T3 (de)
HK (1) HK1049830A1 (de)
HR (1) HRP20020353A2 (de)
HU (1) HU229072B1 (de)
IL (2) IL148782A0 (de)
IS (1) IS2750B (de)
NO (1) NO323320B1 (de)
NZ (1) NZ518296A (de)
SE (1) SE0002320D0 (de)
UA (1) UA73748C2 (de)
WO (1) WO2001030758A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
BRPI0617477A2 (pt) 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CN101466379B (zh) 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
EP2065380A1 (de) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridonamid-Derivate als Focal-Adhesion-Kinase (FAK) Hemmer und deren Verwendung zur Behandlung von Krebs
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
AU2009288108B2 (en) 2008-09-03 2013-10-17 Teva Pharmaceutical Industries, Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
KR20130065728A (ko) * 2010-10-14 2013-06-19 임뮤나르 에이비 Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2537517A1 (de) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-angereichertes 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluor-methyl)phenyl]-1,2-dihydrochinolin-3-carboxamid
EP2819670B1 (de) 2012-02-27 2026-05-20 Vertex Pharmaceuticals Incorporated Pharmazeutische zubereitung und deren verabreichungen
EA201590788A1 (ru) * 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
JP2016514162A (ja) 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
EP3041472B1 (de) * 2014-09-23 2017-02-01 Active Biotech AB Chinolincarboxamide zur verwendung bei der behandlung von multiplem myelom
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
BR112017009854B1 (pt) * 2014-11-19 2022-08-23 Active Biotech Ab Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
US12478621B2 (en) * 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
KR102978225B1 (ko) 2020-03-03 2026-06-15 액티브 바이오테크 에이비 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염
JP2023527782A (ja) * 2020-05-21 2023-06-30 ステムシナジー セラピューティクス， インク． Ｎｏｔｃｈ阻害剤及びその使用
WO2022152902A1 (en) 2021-01-18 2022-07-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
KR20240012436A (ko) * 2021-05-25 2024-01-29 액티브 바이오테크 에이비 복수의 타스퀴니모드 입자 및 그 용도
CA3221689A1 (en) 2021-07-02 2023-01-05 Hans Wannman A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
AR126963A1 (es) 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr
TWI838849B (zh) * 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑
CA3241699A1 (en) * 2021-12-20 2023-06-29 The Johns Hopkins University Compounds for treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
HU229072B1 (en) 2013-07-29
IL148782A0 (en) 2002-09-12
EP1224172A1 (de) 2002-07-24
DE60034240T2 (de) 2007-12-20
DE60034240D1 (de) 2007-05-16
NO20021932D0 (no) 2002-04-24
JP3950337B2 (ja) 2007-08-01
EE200200207A (et) 2003-06-16
SE0002320D0 (sv) 2000-06-21
KR100597938B1 (ko) 2006-07-06
HUP0203238A2 (hu) 2003-01-28
HUP0203238A3 (en) 2003-05-28
IS6329A (is) 2002-04-02
ES2280258T3 (es) 2007-09-16
KR20020043646A (ko) 2002-06-10
HRP20020353A2 (en) 2005-10-31
CA2386775C (en) 2004-07-13
EP1224172B1 (de) 2007-04-04
CA2386775A1 (en) 2001-05-03
CZ298534B6 (cs) 2007-10-31
NO323320B1 (no) 2007-03-12
JP2003512454A (ja) 2003-04-02
NZ518296A (en) 2003-06-30
KR20060054496A (ko) 2006-05-22
IL148782A (en) 2007-05-15
DK1224172T3 (da) 2007-08-13
KR100674160B1 (ko) 2007-01-24
UA73748C2 (en) 2005-09-15
IS2750B (is) 2011-08-15
AU775057B2 (en) 2004-07-15
HK1049830A1 (zh) 2003-05-30
WO2001030758A1 (en) 2001-05-03
CZ20021293A3 (cs) 2002-07-17
AU1185101A (en) 2001-05-08
NO20021932L (no) 2002-06-21

Similar Documents

Publication Publication Date Title
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
YU23202A (sh) Lekovi za tretman malignih tumora
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
IS2114B (is) Kínasólínafleiður til að meðhöndla æxli
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
SE9904505D0 (sv) Novel compounds
GB0112348D0 (en) Compounds
SE0104140D0 (sv) Novel Compounds
PL367682A1 (en) Dolastatin 10 derivatives
DE50310516D1 (de) Fredericamycin-derivate
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
ATE233754T1 (de) Diphenyl-piperidin derivate
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
MXPA04005809A (es) Inhibidores de proteinas quinasas.
SE9902551D0 (sv) Novel compounds
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
BR0116123A (pt) Carbazóis antitumorais
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
CY1106576T1 (el) Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties